During Kenyan Trials, Scientists Revealed That A Single-Dose HPV Vaccine Is 98% Effective

Researchers from the Massachusetts General Hospital (MGH) and the Kenya Medical Research Institute (Kemri) report that a single dosage of the HPV vaccine is 98 percent effective over a three-year period.

The vaccine was found to be highly effective in preventing persistent infections of the virus after a randomized, multicenter, double-blind controlled trial, according to the findings of the KEN SHE study, which was conducted in Kenya. The findings were presented on Wednesday evening at the 35th International Papillomavirus Conference in Washington, D.C.

2,275 Kenyan women between the ages of 15 and 20 participated in the study and were randomized to either receive a single dose of the bivalent or nonavalent HPV vaccine or the control vaccine.

Participants in the 36-month trial were routinely tested for HPV DNA, and cervical and vaginal swabs were taken on a regular basis. According to the findings, both the bivalent and nonavalent HPV vaccinations were very effective when given in a single dosage, with a vaccine efficacy of 98%. Additionally, for the nine strains of HPV it targets, the nonavalent vaccination achieved a vaccine efficacy of 96%, according to an official statement.

The study’s results, they continued, have important ramifications for preventing cervical cancer, which is brought on by ongoing HPV infections.

“A single-dose vaccination schedule may be easier to administer and less expensive than multi-dose regimens, making it a more practical choice in low-resource environments. Only 33% of the targeted girl population in Kenya is currently receiving the first HPV dosage, and only 16% are returning for the second dose, they reported.

Because of this, the scientists believe that a single-dose immunization regimen could significantly reduce this fatal disparity.

The Lead Investigator Dr. Ruanne Barnabas of the Massachusetts General Hospital stated, “This study provides important evidence that a single dose of HPV vaccine can be highly effective in preventing persistent infections, and ultimately, cervical cancer.”

According to the primary researcher, more than 90% of the anticipated 342,000 deaths from cervical cancer in 2020 took place in low- and middle-income nations.